Breaking News
Get 45% Off 0
Special Webinar: WarrenAI Unveiled in a Live Demo Session
Watch Webinar
Close

Ascentage Pharma Grp International (6855)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
51.50 +0.85    +1.68%
13:29:59 - Closed. Currency in HKD
Type:  Equity
Market:  Hong Kong
ISIN:  KYG0519B1023 
  • Volume: 6,660,602
  • Bid/Ask: 51.50 / 51.40
  • Day's Range: 49.85 - 52.65
Ascentage Pharma 51.50 +0.85 +1.68%

Ascentage Pharma Company Profile

 
Explore the Ascentage Pharma company profile for core details about Ascentage Pharma, assess Ascentage Pharma company details, including a description of the company, key contact information, and insights into the top executives. Discover the company's operations and leadership to better understand its role in the industry.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

567

Equity Type

ORD

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin’s lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is also involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.

Contact Information

Address Suzhou Industrial Park 68 Xinqing Road
Suzhou, 215000
China
Phone 86 512 8555 7777
Fax -

Top Executives

Name Age Since Title
Hagop M. Kantarjian - 2023 Member of Clinical Advisory Board
Changqing Ye 53 2019 Independent Non-Executive Director
Shaomeng Wang 58 2017 Co-Founder, Chief Scientific Advisor & Non-Executive Director
Dajun Yang 60 2009 Co-Founder, Chairman & CEO
Allen S. Lichter 77 2023 Chairman of the Clinical Advisory Board
Jedd D. Wolchok - 2021 Member of Clinical Advisory Board
Wei Ren 43 2019 Independent Non-Executive Director
Asher A. Chanan-Khan - 2023 Member of Clinical Advisory Board
Jiuyun Yu 59 2024 Independent Non-Executive Director
Marina S. Bozilenko 59 2024 Independent Non-Executive Director
Hagop M. Kantarjian - 2023 Member of Clinical Advisory Board
Arul M. Chinnaiyan - - Member of Clinical Advisory Board
Dazhong Lu 56 2018 Independent Non-Executive Director
Paul A. Bunn 79 - Member of Clinical Advisory Board
David Sidransky 65 2021 Independent Non-Executive Director
Marc Estes Lippman 80 2025 Independent Non-Executive Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

6855 Comments

Write your thoughts about Ascentage Pharma Grp International
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email